New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
05:50 EDTFRXForest Labs announces positive Phase IIb top-line results for cariprazine
Forest Laboratories and Gedeon Richter announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine as adjunctive treatment in adult patients with Major Depressive Disorder who have demonstrated an inadequate response to antidepressant therapy, or ADT. The trial consisted of three treatment groups. The group who received cariprazine 2.0 4.5 mg/day + ADT demonstrated statistically significant improvement in the Montgomery-Asberg Depression Rating Scale total score versus placebo at 8 weeks, the primary endpoint.
News For FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for FRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use